Micafungin Teva

Micafungin, the active ingredient in Micafungin Teva, is an echinocandin presented as a intravenous solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for Candida prophylaxis in hematopoietic stem cell transplantation. GNH USA supplies Micafungin Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal used to treat serious Candida infections.

- Invasive candidiasis: effective for bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: clears fungal infection of the esophagus. - Candida prophylaxis in hematopoietic stem cell transplantation: prevents invasive Candida disease in transplant recipients.

Micafungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury with jaundice. - Severe hypersensitivity: anaphylaxis or extensive skin rash. - Infusion‑related reactions: hypotension, dyspnea, or chest pain.

Before using Micafungin, consider the following precautions. - Renal impairment: monitor kidney function in patients with reduced clearance. - Hepatic dysfunction: assess liver enzymes prior to therapy. - Concomitant azoles: avoid co‑administration with strong CYP3A4 inhibitors. - Pregnancy: use only if potential benefit justifies risk; data limited. - Pediatric use: safety not established in children under 1 month. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; key interactions are:

Major Interactions (Avoid): - Cyclosporine: increased micafungin exposure; may require dose adjustment. - Rifampin: reduced micafungin levels; may diminish efficacy. - Strong CYP3A4 inducers (e.g., carbamazepine): lower micafungin concentrations.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): potential additive hepatotoxicity. - Warfarin: monitor INR as micafungin may affect anticoagulation. - Immunosuppressants (e.g., tacrolimus): observe drug levels for possible changes.